Anzeige
Mehr »
Dienstag, 23.06.2026 - Börsentäglich über 12.000 News
Schuldenfrei, 1,5 Mio. Unzen Gold und Produktion ab 2027: Vor dem Ausbruch?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
187 Leser
Artikel bewerten:
(1)

miDiagnostics and CEO Katleen Verleysen Recognised in Business Worldwide Magazine's 2026 Global Corporate Excellence Awards

LONDON, June 23, 2026 /PRNewswire/ -- miDiagnostics and its CEO Katleen Verleysen have been recognised in Business Worldwide Magazine's 2026 Global Corporate Excellence Awards, which continue to shine a spotlight on the relentless pursuit of excellence in the corporate world. These accolades recognize companies and their visionary leaders who have demonstrated unwavering commitment to innovation, ethical standards, and outstanding performance.

miDiagnostics received the title of "MedTech Company of the Year - Breakthrough Diagnostic Technology | Europe", while Katleen Verleysen was recognised with the award for "Outstanding Leadership in Clinical Molecular Diagnostics | Europe."

Based in Leuven, Belgium, miDiagnostics develops ultra-fast PCR-based testing technology designed to support the safe and rapid delivery of advanced immunotherapies, including CAR-T cancer treatments.

The company's technology enables sterility testing results in under two hours rather than several days, helping pharmaceutical manufacturers accelerate treatment delivery while maintaining strict safety and regulatory standards.

As personalised medicine continues to transform healthcare, the speed and reliability of testing technologies have become increasingly critical. CAR-T therapies, which use a patient's own immune cells to fight cancer, require highly specialised manufacturing processes and rigorous sterility validation before treatments can be administered.

Traditional sterility testing methods can create significant delays, particularly for patients with aggressive cancers where time is critical. miDiagnostics addresses this challenge through advanced PCR technology capable of rapidly detecting microbial contamination and supporting faster treatment release.

Under Verleysen's leadership, the company has accelerated its commercial growth and international positioning within the rapidly evolving life sciences sector.

A trained chemist with a PhD background, Verleysen has combined scientific expertise with strategic leadership to help scale miDiagnostics from a research-driven organisation into an internationally recognised medtech company.

Since joining the company as CEO in 2021, she has focused on building the operational and commercial infrastructure needed to support global growth, while strengthening partnerships across the pharmaceutical and healthcare industries.

Today, miDiagnostics collaborates with leading organisations, and working with major pharmaceutical companies to evaluate and implement rapid sterility testing solutions in advanced therapy manufacturing environments.

The company's technology is positioned to support not only oncology treatments, but also the broader future of immunotherapy, including applications in autoimmune diseases and other complex conditions where personalised medicine is expected to play a transformative role.

The dual recognition highlights both miDiagnostics' scientific innovation and the leadership driving its continued expansion in the global healthcare sector.

Commenting on the recognition, Katleen Verleysen said: "I am deeply honoured by this recognition and proud of what our team has achieved together. At miDiagnostics, we are driven by the belief that innovation should ultimately serve patients. This award reflects the scientific excellence, collaboration, and dedication of our team as we continue to help accelerate the delivery of advanced therapies to patients worldwide."

In recent years, the company and its leadership have received multiple international recognitions, including Top MedTech Startup in Europe, European CEO of the Year 2024 and 2025, Top Innovative Chief Executive Officer in Life Sciences at BIO-Europe 2025 and the Burj CEO award for 'Exemplary Woman of Achievement' 2025.

As the healthcare industry increasingly shifts toward faster, smarter, and more personalised treatments, miDiagnostics continues to position itself at the forefront of diagnostic innovation, helping pharmaceutical partners deliver advanced therapies more safely, efficiently, and rapidly to patients worldwide.

For more information, visit miDiagnostics.

For more information about the Global Corporate Excellence Awards, visit Business Worldwide Magazine Awards.

About Business Worldwide Magazine

Business Worldwide Magazine is the leading source of business and dealmaker intelligence throughout the world. Our quarterly magazine and online news portal enable an established audience of corporate dealmakers to track the latest news, stories and developments affecting the international markets, corporate finance, business strategy and changes in legislation. This readership includes CEO/CFO - Banks, Corporate Lawyers and Venture Capital/Private Equity Companies to name a few.

Contact
David Jones
Awards Department
E: david@bwmonline.com

W: www.bwmonline.com

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/midiagnostics-and-ceo-katleen-verleysen-recognised-in-business-worldwide-magazines-2026-global-corporate-excellence-awards-302804846.html

© 2026 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.